Prescription Medicines Partnering
With more than 50% of our early-mid stage pipeline anchored in external collaborations, we are committed to pursuing, with our partners, the healthcare solutions of the future
Research & Development
Boehringer Ingelheim has a proven track record of developing new treatments in its core therapeutic areas and continues to explore novel compounds with the aim of further advancing therapy for patients in areas of high unmet medical need.
How We Discover
From initial discovery to a marketable medicine is a long, challenging road. It takes about 12 - 15 years from discovery to the approved medication and requires an investment of about US $1 billion.
14 Jul 2016 at 11:00
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
13 Jul 2016 at 14:00
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
07 Jul 2016 at 15:00
Marina von Keyserlingk and Daniel Weary win first Ruminant Well-being Award
07 Jun 2016 at 16:00
Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
31 May 2016 at 10:00
Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis